Suvretta Capital Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-107,310
| Closed | -$2.52M | – | 110 |
|
|
2024
Q2 | $2.52M | Sell |
107,310
-55,085
| -34% | -$1.3M | 0.09% | 66 |
|
|
2024
Q1 | $6.16M | Hold |
162,395
| – | – | 0.23% | 60 |
|
|
2023
Q4 | $3.49M | Hold |
162,395
| – | – | 0.16% | 59 |
|
|
2023
Q3 | $1.99M | Sell |
162,395
-1
| -0% | -$12 | 0.11% | 65 |
|
|
2023
Q2 | $1.83M | Hold |
162,396
| – | – | 0.1% | 76 |
|
|
2023
Q1 | $1.18M | Hold |
162,396
| – | – | 0.05% | 75 |
|
|
2022
Q4 | $1.83M | Hold |
162,396
| – | – | 0.08% | 67 |
|
|
2022
Q3 | $2.14M | Hold |
162,396
| – | – | 0.09% | 63 |
|
|
2022
Q2 | $2.05M | Hold |
162,396
| – | – | 0.08% | 78 |
|
|
2022
Q1 | $9.34M | Buy |
162,396
+59,556
| +58% | +$3.42M | 0.29% | 54 |
|
|
2021
Q4 | $12.2M | Buy |
102,840
+16,531
| +19% | +$1.96M | 0.24% | 58 |
|
|
2021
Q3 | $17.2M | Buy |
86,309
+2,545
| +3% | +$506K | 0.29% | 50 |
|
|
2021
Q2 | $14.6M | Buy |
83,764
+29,081
| +53% | +$5.06M | 0.22% | 68 |
|
|
2021
Q1 | $10.8M | Buy |
54,683
+24,333
| +80% | +$4.82M | 0.16% | 72 |
|
|
2020
Q4 | $5.97M | Buy |
30,350
+9,186
| +43% | +$1.81M | 0.09% | 71 |
|
|
2020
Q3 | $3.75M | Buy |
21,164
+16,447
| +349% | +$2.91M | 0.07% | 68 |
|
|
2020
Q2 | $1.09M | Buy |
+4,717
| New | +$1.09M | 0.02% | 77 |
|